Granulocytes and mast cells in AllergoOncology-Bridging allergy to cancer: An EAACI position paper.
AllergoOncology
allergy
basophils
cancer
eosinophils
granulocytes
mast cells
neutrophils
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
22 Jul 2024
22 Jul 2024
Historique:
revised:
23
06
2024
received:
25
04
2024
accepted:
11
07
2024
medline:
22
7
2024
pubmed:
22
7
2024
entrez:
22
7
2024
Statut:
aheadofprint
Résumé
Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss common granulocyte and mast cell features relating to immunomodulatory functions in allergy and in cancer. We highlight key mechanisms which may inform cancer treatment and propose pertinent areas for future research. We suggest areas where understanding the communication between granulocytes, mast cells, and the tumor microenvironment, will be crucial for identifying immune mechanisms that may be harnessed to counteract tumor development. For example, a comprehensive understanding of allergic and immune factors driving distinct neutrophil states and those mechanisms that link mast cells with immunotherapy resistance, might enable targeted manipulation of specific subpopulations, leading to precision immunotherapy in cancer. We recommend specific areas of investigation in AllergoOncology and knowledge exchange across disease contexts to uncover pertinent reciprocal functions in allergy and cancer and allow therapeutic manipulation of these powerful cell populations. These will help address the unmet needs in stratifying and managing patients with allergic diseases and cancer.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Jensen‐Jarolim E, Bax HJ, Bianchini R, et al. AllergoOncology–the impact of allergy in oncology: EAACI position paper. Allergy. 2016;72(6):866‐887. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28032353
Jutel M, Agache I, Zemelka‐Wiacek M, et al. Nomenclature of allergic diseases and hypersensitivity reactions: adapted to modern needs: an EAACI position paper. Allergy. 2023;78(11):2851‐2874.
Abbas APS. Innate immunity. Cellular Molecular Immunology. 10th ed. Elsevier; 2021.
Jensen‐Jarolim E, Bax HJ, Bianchini R, et al. AllergoOncology: opposite outcomes of immune tolerance in allergy and cancer. Allergy. 2017;73(2):328‐340. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28921585
Bergmann C, Poli A, Agache I, et al. AllergoOncology: danger signals in allergology and oncology: a European academy of allergy and clinical immunology (EAACI) position paper. Allergy. 2022;77(9):2594‐2617. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35152450
Chauhan J, Stavraka C, Grandits M, et al. Clinical and translational significance of basophils in patients with cancer. Cells. 2022;11(3):438. doi:10.3390/cells11030438
Fereydouni M, Ahani E, Desai P, et al. Human tumor targeted cytotoxic mast cells for cancer immunotherapy. Front Oncol. 2022;12:871390. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35574362
Tauber M, Basso L, Martin J, et al. Correction: landscape of mast cell populations across organs in mice and humans. J Exp Med. 2024;221(2):e2023057001172024c. doi:10.1084/jem.2023057001172024c
Ghafouri‐Fard S, Niazi V, Taheri M. Role of miRNAs and lncRNAs in hematopoietic stem cell differentiation. Noncoding RNA Res. 2021;6(1):8‐14. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33385102
Knol EFKTW. Neutrophils, eosinophils and basophils in the skin immune system. Skin Immune system. 3rd ed. CRC Press LLC; 2004.
Tsai CY, Hsieh SC, Liu CW, et al. Cross‐talk among Polymorphonuclear neutrophils, immune, and non‐immune cells via released cytokines, granule proteins, microvesicles, and neutrophil extracellular trap formation: a novel concept of biology and pathobiology for neutrophils. Int J Mol Sci. 2021;22(6):3119‐3126. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33803773
Varricchi G, Raap U, Rivellese F, Marone G, Gibbs BF. Human mast cells and basophils‐how are they similar how are they different? Immunol Rev. 2018;282(1):8‐34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29431214
Fettrelet T, Gigon L, Karaulov A, Yousefi S, Simon HU. The enigma of eosinophil degranulation. Int J Mol Sci. 2021;22(13):7091‐7109. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34209362
Haus E, Smolensky MH. Biologic rhythms in the immune system. Chronobiol Int. 1999;16(5):581‐622.
Cox SL, O'Siorain JR, He Y, et al. Circadian disruption in lung fibroblasts enhances NF‐κB activity to exacerbate neutrophil recruitment. FASEB J. 2023;37(2):1‐14. Available from: https://pubmed.ncbi.nlm.nih.gov/36624683/
Aroca‐Crevillén A, Adrover JM, Hidalgo A. Circadian features of neutrophil biology. Front Immunol. 2020;3(11):514746.
Zhang Z, Zeng P, Gao W, Zhou Q, Feng T, Tian X. Circadian clock: a regulator of the immunity in cancer. Cell Commun Signal. 2021;19(1):1‐12.
Amidi A, Wu LM. Circadian disruption and cancer‐ and treatment‐related symptoms. Front Oncol. 2022;12:1009064. Available from http://www.ncbi.nlm.nih.gov/pubmed/36387255
Burn GL, Foti A, Marsman G, Patel DF, Zychlinsky A. The neutrophil. Immunity. 2021;54(7):1377‐1391. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34260886
Gigon L, Fettrelet T, Yousefi S, Simon D, Simon HU. Eosinophils from a to Z. Allergy. 2023;78(7):1810‐1846. Available from: https://pubmed.ncbi.nlm.nih.gov/37102676/
Shen K, Zhang M, Zhao R, et al. Eosinophil extracellular traps in asthma: implications for pathogenesis and therapy. Respir Res. 2023;24(1):231. doi:10.1186/s12931-023-02504-4
Lu Y, Huang Y, Li J, et al. Eosinophil extracellular traps drive asthma progression through neuro‐immune signals. Nat Cell Biol. 2021;23(10):1060‐1072. Available from: https://pubmed.ncbi.nlm.nih.gov/34616019/
Bhattacharyya S, Oon C, Diaz L, et al. Autotaxin‐lysolipid signaling suppresses a CCL11‐eosinophil axis to promote pancreatic cancer progression. Nat Cancer. 2024;5(2):283‐298. Available from: http://www.ncbi.nlm.nih.gov/pubmed/38195933
Toyohara T, Yoshida M, Miyabe K, et al. Dual role of autotaxin as novel biomarker and therapeutic target in pancreatic neuroendocrine neoplasms. Cancer Sci. 2023;114(12):4571‐4582. Available from: https://pubmed.ncbi.nlm.nih.gov/37770812/
She S, Zhang Q, Shi J, Yang F, Dai K. Roles of autotaxin/autotaxin‐lysophosphatidic acid Axis in the initiation and progression of liver cancer. Front Oncol. 2022;12:922945. Available from: https://pubmed.ncbi.nlm.nih.gov/35769713/
Benesch MGK, Tang X, Brindley DN, Takabe K. Autotaxin and lysophosphatidate signaling: prime targets for mitigating therapy resistance in breast cancer. World J Oncol. 2024;15(1):1‐13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/38274724
Grisaru‐Tal S, Munitz A. ATX restricts anti‐tumor eosinophil responses. Nat Can. 2024;5(2):221‐223.
Jesenak M, Diamant Z, Simon D, et al. Eosinophils—from cradle to grave. Allergy: European. J Allergy Clin Immunol. 2023;78(12):3077‐3102.
Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. Allergy. 2021;76(8):2420‐2432. doi:10.1111/all.14747
Knol EF, Mul FPJ, Jansen H, Calafat J, Roos D. Monitoring human basophil activation via CD63 monoclonal antibody 435. J Allergy Clin Immunol. 1991;88(3 Pt 1):328‐338. Available from: https://pubmed.ncbi.nlm.nih.gov/1716273/
Ebo DG, Bridts CH, Mertens CH, Hagendorens MM, Stevens WJ, De Clerck LS. Analyzing histamine release by flow cytometry (HistaFlow): a novel instrument to study the degranulation patterns of basophils. J Immunol Methods. 2012;375(1–2):30‐38. Available from: https://pubmed.ncbi.nlm.nih.gov/21945198/
Elst J, van der Poorten MLM, Van Gasse AL, et al. Mast cell activation tests by flow cytometry: a new diagnostic asset? Clin Exp Allergy. 2021;51(11):1482‐1500. Available from: https://pubmed.ncbi.nlm.nih.gov/34233046/
McNeil BD, Pundir P, Meeker S, et al. Identification of a mast‐cell‐specific receptor crucial for pseudo‐allergic drug reactions. Nature. 2015;519(7542):237‐241. Available from: https://pubmed.ncbi.nlm.nih.gov/25517090/
Plum T, Binzberger R, Thiele R, et al. Mast cells link immune sensing to antigen‐avoidance behaviour. Nature. 2023;620(7974):634‐642. doi:10.1038/s41586-023-06188-0
Florsheim EB, Bachtel ND, Cullen JL, et al. Immune sensing of food allergens promotes avoidance behaviour. Nature. 2023;620(7974):643‐650. doi:10.1038/s41586-023-06362-4
Jonsson F, de Chaisemartin L, Granger V, et al. An IgG‐induced neutrophil activation pathway contributes to human drug‐induced anaphylaxis. Sci Transl Med. 2019;11(500):eaat1479. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31292264
Polak D, Hafner C, Briza P, et al. A novel role for neutrophils in IgE‐mediated allergy: evidence for antigen presentation in late‐phase reactions. J Allergy Clin Immunol. 2018;143(3):1143‐1152. e4. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29920351
Ray A, Kolls JK. Neutrophilic inflammation in asthma and association with disease severity. Trends Immunol. 2017;38(12):942‐954. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28784414
Radermecker C, Louis R, Bureau F, Marichal T. Role of neutrophils in allergic asthma. Curr Opin Immunol. 2018;54:28‐34. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29883877
Mora J, Riggs EK, Fu J, et al. Expression of the high affinity IgE receptor by neutrophils of individuals with allergic asthma is both minimal and insensitive to regulation by serum IgE. Clin Immunol. 2009;132(1):132‐140. Available from: https://pubmed.ncbi.nlm.nih.gov/19359220/
Papayannopoulos V. Neutrophil extracellular traps in immunity and disease. Nat Rev Immunol. 2017;18(2):134‐147. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28990587
Toussaint M, Jackson DJ, Swieboda D, et al. Host DNA released by NETosis promotes rhinovirus‐induced type‐2 allergic asthma exacerbation. Nat Med. 2017;23(6):681‐691. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28459437
Arebro J, Ekstedt S, Hjalmarsson E, Winqvist O, Kumlien Georen S, Cardell LO. A possible role for neutrophils in allergic rhinitis revealed after cellular subclassification. Sci Rep. 2017;7:43568. Available from: https://www.ncbi.nlm.nih.gov/pubmed/28272395
Dawicki W, Jawdat DW, Xu N, Marshall JS. Mast cells, histamine, and IL‐6 regulate the selective influx of dendritic cell subsets into an inflamed lymph node. J Immunol. 2010;184(4):2116‐2123. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20083654
Komi DEA, Redegeld FA. Role of mast cells in shaping the tumor microenvironment. Clin Rev Allergy Immunol. 2019;58(3):313‐325.
Somasundaram R, Connelly T, Choi R, et al. Tumor‐infiltrating mast cells are associated with resistance to anti‐PD‐1 therapy. Nat Commun. 2021;12(1):346. Available from: https://www.ncbi.nlm.nih.gov/pubmed/33436641
Reddy SM, Reuben A, Barua S, et al. Poor response to neoadjuvant chemotherapy correlates with mast cell infiltration in inflammatory breast cancer. Cancer. Immunol Res. 2019;7(6):1025‐1035.
Longo V, Catino A, Montrone M, Galetta D, Ribatti D. Controversial role of mast cells in NSCLC tumor progression and angiogenesis. Thorac. Cancer. 2022;13(21):2929‐2934.
Johansson A, Rudolfsson S, Hammarsten P, et al. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010;177(2):1031‐1041. Available from: https://www.ncbi.nlm.nih.gov/pubmed/20616342
Yu Y, Blokhuis B, Derks Y, Kumari S, Garssen J, Redegeld F. Human mast cells promote colon cancer growth via bidirectional crosstalk: studies in 2D and 3D coculture models. Oncoimmunology. 2018;7(11):e1504729. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30377568
Rabenhorst A, Schlaak M, Heukamp LC, et al. Mast cells play a protumorigenic role in primary cutaneous lymphoma. Blood. 2012;120(10):2042‐2054. Available from: https://pubmed.ncbi.nlm.nih.gov/22837530/
Annese T, Tamma R, Bozza M, Zito A, Ribatti D. Autocrine/paracrine loop between SCF+/c‐kit+ mast cells promotes cutaneous melanoma progression. Front Immunol. 2022;13:794974.
Aponte‐López A, Muñoz‐Cruz S. Mast cells in the tumor microenvironment. Adv Exp Med Biol. 2020;1273:159‐173.
Bao X, Shi R, Zhao T, Wang Y. Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma. Mol Oncol. 2020;14(5):917‐932.
Chan JK, Magistris A, Loizzi V, et al. Mast cell density, angiogenesis, blood clotting, and prognosis in women with advanced ovarian cancer. Gynecol Oncol. 2005;99(1):20‐25. Available from: https://www.ncbi.nlm.nih.gov/pubmed/16055178
McHale C, Mohammed Z, Gomez G. Human skin‐derived mast cells spontaneously secrete several angiogenesis‐related factors. Front Immunol. 2019;10:1445. Available from: https://www.ncbi.nlm.nih.gov/pubmed/31293594
Johnston RL, Mottok A, Chan FC, et al. A gene expression‐based model predicts outcome in children with intermediate‐risk classical Hodgkin lymphoma. Blood. 2021;139(6):889‐893.
Lichterman JN, Reddy SM. Mast cells: a new frontier for cancer immunotherapy. Cells. 2021;10(6):1270‐1287. Available from: https://www.ncbi.nlm.nih.gov/pubmed/34063789
Jachetti E, Cancila V, Rigoni A, et al. Cross‐talk between myeloid‐derived suppressor cells and mast cells mediates tumor‐specific immunosuppression in prostate cancer. Cancer Immunol Res. 2018;6(5):552‐565. Available from: https://www.ncbi.nlm.nih.gov/pubmed/29523597
Segura‐Villalobos D, Ramirez‐Moreno IG, Martinez‐Aguilar M, et al. Mast cell‐tumor interactions: molecular mechanisms of recruitment, Intratumoral communication and potential therapeutic targets for tumor growth. Cells. 2022;11(3):349‐366. Available from: https://www.ncbi.nlm.nih.gov/pubmed/35159157
Cai Z, Tang B, Chen L, Lei W. Mast cell marker gene signature in head and neck squamous cell carcinoma. BMC Cancer. 2022;22(1):577.
Ma C, Li F, He Z, Zhao S. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape. Front Surg. 2022;9:1015263.
Baechle JJ, Hanna DN, Sekhar KR, Rathmell JC, Rathmell WK, Baregamian N. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment. Surgery. 2021;171(1):111‐118.
Grisaru‐Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer. 2020;20(10):594‐607. Available from: https://www.ncbi.nlm.nih.gov/pubmed/32678342
Ikutani M, Yanagibashi T, Ogasawara M, et al. Identification of innate IL‐5‐producing cells and their role in lung eosinophil regulation and antitumor immunity. J Immunol. 2012;188(2):703‐713. Available from: https://pubmed.ncbi.nlm.nih.gov/22174445/
Ghaffari S, Rezaei N. Eosinophils in the tumor microenvironment: implications for cancer immunotherapy. J Transl Med. 2023;21(1):551‐573. Available from: https://pubmed.ncbi.nlm.nih.gov/37587450/
Grisaru‐Tal S, Itan M, Grass DG, et al. Primary tumors from mucosal barrier organs drive unique eosinophil infiltration patterns and clinical associations. Oncoimmunology. 2020;10(1):1859732‐1859744. Available from: https://pubmed.ncbi.nlm.nih.gov/33457078/
Grisaru‐Tal S, Dulberg S, Beck L, et al. Metastasis‐entrained eosinophils enhance lymphocyte‐mediated antitumor immunity. Cancer Res. 2021;81(21):5555‐5571.
Hu G, Wang S, Zhong K, et al. Tumor‐associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta‐analysis. BMC Cancer. 2020;20(1):454‐462. Available from: https://pubmed.ncbi.nlm.nih.gov/32434481/
Reichman H, Itan M, Rozenberg P, et al. Activated eosinophils exert antitumorigenic activities in colorectal cancer. Cancer Immunol Res. 2019;7(3):388‐400. Available from: https://www.ncbi.nlm.nih.gov/pubmed/30665890
Mesnil C, Raulier S, Paulissen G, et al. Lung‐resident eosinophils represent a distinct regulatory eosinophil subset. J Clin Invest. 2016;126(9):3279‐3295. Available from: https://www.ncbi.nlm.nih.gov/pubmed/27548519
Caruso R, Caruso V, Rigoli L. Ultrastructural evidence of eosinophil clustering and ETosis in association with damage to single tumour cells in a case of poorly cohesive NOS gastric carcinoma. Eur J Case Rep Intern Med. 2023;10(10):004016‐004019. Available from: https://pubmed.ncbi.nlm.nih.gov/37789981/
Lavin Y, Kobayashi S, Leader A, et al. Innate immune landscape in early lung adenocarcinoma by paired single‐cell analyses. Cell. 2017;169(4):750‐765.e17.
De Monte L, Wormann S, Brunetto E, et al. Basophil recruitment into tumor‐draining lymph nodes correlates with Th2 inflammation and reduced survival in pancreatic cancer patients. Cancer Res. 2016;76(7):1792‐1803.
Sektioglu IM, Carretero R, Bulbuc N, et al. Basophils promote tumor rejection via chemotaxis and infiltration of CD8+ T cells. Cancer Res. 2016;77(2):291‐302.
Bax HJ, Chauhan J, Stavraka C, et al. Basophils from cancer patients respond to immune stimuli and predict clinical outcome. Cells. 2020;9(7):1631‐1651.
He X, Cao Y, Gu Y, et al. Clinical outcomes and immune metrics in Intratumoral basophil‐enriched gastric cancer patients. Ann Surg Oncol. 2021;28(11):6439‐6450.
Hadadi A, Smith KE, Wan L, et al. Baseline basophil and basophil‐to‐lymphocyte status is associated with clinical outcomes in metastatic hormone sensitive prostate cancer. Urol Oncol. 2022;40(6):e9‐e18.
Wu C, Qiu Y, Zhang R, et al. Association of peripheral basophils with tumor M2 macrophage infiltration and outcomes of the anti‐PD‐1 inhibitor plus chemotherapy combination in advanced gastric cancer. J Transl Med. 2022;20(1):386‐400.
Wei Y, Zhang X, Wang G, et al. The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage I–III colorectal cancer. Asia Pac J Clin Oncol. 2018;14(5):e243‐e251.
Liu Q, Luo D, Cai S, Li Q, Li X. Circulating basophil count as a prognostic marker of tumor aggressiveness and survival outcomes in colorectal cancer. Clin Transl Med. 2020;9(1):6‐18.
Zheng L, Yu M, Zhang S. Prognostic value of pretreatment circulating basophils in patients with glioblastoma. Neurosurg Rev. 2021;44(6):3471‐3478.
Schwager C, Kull S, Behrends J, et al. Peanut oleosins associated with severe peanut allergy‐importance of lipophilic allergens for comprehensive allergy diagnostics. J Allergy Clin Immunol. 2017;140(5):1331‐1338.
Mehlich J, Fischer J, Hilger C, et al. The basophil activation test differentiates between patients with alpha‐gal syndrome and asymptomatic alpha‐gal sensitization. J Allergy Clin Immunol. 2019;143(1):182‐189.
Behrends J, Schwager C, Hein M, Scholzen T, Kull S, Jappe U. Innovative robust basophil activation test using a novel gating strategy reliably diagnosing allergy with full automation. Allergy. 2021;76(12):3776‐3788.
Bax HJ, Khiabany A, Stavraka C, et al. Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti‐tumor IgE therapeutic candidate. Allergy. 2020;75(8):2069‐2073.
Chauhan J, McCraw A, Nakamura M, et al. IgE antibodies against cancer: efficacy and safety. Antibodies. 2020;9(4):55.
Shaul ME, Fridlender ZG. Tumour‐associated neutrophils in patients with cancer. Nat Rev Clin Oncol. 2019;16(10):601‐620.
Masucci MT, Minopoli M, Del Vecchio S, Carriero MV. The emerging role of neutrophil extracellular traps (NETs) in tumor progression and metastasis. Front Immunol. 2020;11:554635.
Shao BZ, Yao Y, Li JP, Chai NL, Linghu EQ. The role of neutrophil extracellular traps in cancer. Front Oncol. 2021;12:11.
Hedrick CC, Malanchi I. Neutrophils in cancer: heterogeneous and multifaceted. Nat Rev Immunol. 2021;22(3):173‐187.
Jaillon S, Ponzetta A, Di Mitri D, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat Rev Cancer. 2020;20(9):485‐503.
Montaldo E, Lusito E, Bianchessi V, et al. Cellular and transcriptional dynamics of human neutrophils at steady state and upon stress. Nat Immunol. 2022;23(10):1470‐1483.
Shaul ME, Eyal O, Guglietta S, et al. Circulating neutrophil subsets in advanced lung cancer patients exhibit unique immune signature and relate to prognosis. FASEB J. 2020;34(3):4204‐4218.
Zhu YP, Eggert T, Araujo DJ, Vijayanand P, Ottensmeier CH, Hedrick CC. CyTOF mass cytometry reveals phenotypically distinct human blood neutrophil populations differentially correlated with melanoma stage. J Immunother cancer. 2020;8(2):e000473‐e000484.
Quail DF, Amulic B, Aziz M, et al. Neutrophil phenotypes and functions in cancer: a consensus statement. J Exp Med. 2022;219(6):e20220011‐e20220022.
Song M, Graubard BI, Rabkin CS, Engels EA. Neutrophil‐to‐lymphocyte ratio and mortality in the United States general population. Sci Rep. 2021;11(1):464.
Gago‐Dominguez M, Matabuena M, Redondo CM, et al. Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions. Sci Rep. 2020;10(1):13203.
Ocana A, Nieto‐Jimenez C, Pandiella A, Templeton AJ. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer. 2017;16(1):137.
Zhang Y, Guo L, Dai Q, et al. A signature for pan‐cancer prognosis based on neutrophil extracellular traps. J Immunother Cancer. 2022;10(6):13203‐13214.
Bagchi S, Yuan R, Engleman EG. Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance. Annu Rev Pathol. 2021;16:223‐249.
Kaushik I, Ramachandran S, Zabel C, Gaikwad S, Srivastava SK. The evolutionary legacy of immune checkpoint inhibitors. Semin Cancer Biol. 2022;1(86):491‐498.
Sharma P, Goswami S, Raychaudhuri D, et al. Immune checkpoint therapy‐current perspectives and future directions. Cell. 2023;186(8):1652‐1669.
Morad G, Helmink BA, Sharma P, Wargo JA. Hallmarks of response, resistance, and toxicity to immune checkpoint blockade. Cell. 2021;184(21):5309‐5337.
Morad G, Helmink BA, Sharma P, Wargo JA. Erratum: Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (Cell) (2021) 184(21) (5309–5337), S0092867421011016. Cell. 2022;185(3):576. doi:10.1016/j.cell.2021.09.020
Zhou B, Gao Y, Zhang P, Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;14:12.
Li H, Xiao Y, Li Q, et al. The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022;40(1):36‐52.
Chen H, Lin R, Lin W, et al. An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma. Sci Rep. 2022;12(1):8230.
Bordon Y. Antitumour roles for antihistamines. Nat Rev Immunol. 2022;22(1):4‐5.
Das S, Johnson DB. Immune‐related adverse events and anti‐tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):411‐424.
Lv Y, Zhao Y, Wang X. Correction: increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF‐α‐PD‐L1 pathway. J Immunother Cancer. 2020;8(2):e0530‐3corr1.
Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Toxicol. 2022;17. doi:10.1007/s13181-021-00833-8
Huang J, Zhang L, Chen J, et al. The landscape of immune cells indicates prognosis and applicability of checkpoint therapy in hepatocellular carcinoma. Front Oncol. 2021;11:744951.
Yang S, Wu Y, Deng Y, et al. Identification of a prognostic immune signature for cervical cancer to predict survival and response to immune checkpoint inhibitors. Onco Targets Ther. 2019;8(12):e1659094.
Han S, Jiang D, Zhang F, et al. A new immune signature for survival prediction and immune checkpoint molecules in non‐small cell lung cancer. Front. Oncologia. 2023;13:1095313.
Guven DC, Sahin TK, Erul E, et al. The association between early changes in neutrophil‐lymphocyte ratio and survival in patients treated with immunotherapy. J Clin Med. 2022;11(15):4523‐4536.
Li M, Spakowicz D, Burkart J, et al. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non‐linear predictor of patient outcomes in advanced cancers. J Cancer Res Clin Oncol. 2019;145(10):2541‐2546.
Gil L, Alves FR, Silva D, et al. prognostic impact of baseline neutrophil‐to‐eosinophil ratio in patients with metastatic renal cell carcinoma treated with Nivolumab therapy in second or later lines. Cureus. 2022;14(2):e22224.
Naszai M, Kurjan A, Maughan TS. The prognostic utility of pre‐treatment neutrophil‐to‐lymphocyte‐ratio (NLR) in colorectal cancer: a systematic review and meta‐analysis. Cancer Med. 2021;10(17):5983‐5997.
Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga‐Taylor AJ. Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta‐analyses of observational studies. BMC Med. 2020;18(1):360‐376.
Chen YW, Tucker MD, Brown LC, et al. The association between a decrease in on‐treatment neutrophil‐to‐eosinophil ratio (NER) at week 6 after Ipilimumab plus Nivolumab initiation and improved clinical outcomes in metastatic renal cell carcinoma. Cancers (Basel). 2022;14(15):3830‐3844.
Alessi JV, Ricciuti B, Alden SL, et al. Low peripheral blood derived neutrophil‐to‐lymphocyte ratio (dNLR) is associated with increased tumor T‐cell infiltration and favorable outcomes to first‐line pembrolizumab in non‐small cell lung cancer. J Immunother Cancer. 2021;9(11):e003536‐e003544.
Guo Y, Xiang D, Wan J, Yang L, Zheng C. Focus on the dynamics of neutrophil‐to‐lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: a meta‐analysis and systematic review. Cancers (Basel). 2022;14(21):5297‐5317.
Capone M, Giannarelli D, Mallardo D, et al. Baseline neutrophil‐to‐lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer. 2018;6(1):74‐81.
Sacdalan DB, Lucero JA, Sacdalan DL. Prognostic utility of baseline neutrophil‐to‐lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta‐analysis. Onco Targets Ther. 2018;11:955‐965.
Tucker MD, Brown LC, Chen YW, et al. Association of baseline neutrophil‐to‐eosinophil ratio with response to nivolumab plus ipilimumab in patients with metastatic renal cell carcinoma. Biomark Res. 2021;9(1):80.
Zhuang TZ, Ravindranathan D, Liu Y, et al. Baseline neutrophil‐to‐eosinophil ratio is associated with outcomes in metastatic renal cell carcinoma treated with immune checkpoint inhibitors. Oncologist. 2023;28(3):239‐245.
Viñal D, Gutierrez‐Sainz L, Martinez D, et al. Prognostic value of neutrophil‐to‐lymphocyte ratio in advanced cancer patients receiving immunotherapy. Clin Transl Oncol. 2021;23(6):1185‐1192.
Blomberg OS, Spagnuolo L, Garner H, et al. IL‐5‐producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell. 2023;41(1):106‐123.
Somasundaram R, Connelly T, Choi R, et al. Tumor‐infiltrating mast cells are associated with resistance to anti‐PD‐1 therapy. Nature Communications 2021 12:1. 2021;12(1):1‐14.
Hirschhorn D, Budhu S, Kraehenbuehl L, et al. T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants. Cell. 2023;186(7):1432‐1447.
Lad BM, Beniwal AS, Jain S, et al. Glioblastoma induces the recruitment and differentiation of hybrid neutrophils from skull bone marrow. bioRxiv. 2023;534105.
Spicer J, Basu B, Montes A, et al. Safety and anti‐tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor‐alpha: a phase I trial. Nature Communications 2023. 2023;14(1):1‐11.
Jiang SH, Zhang XX, Hu LP, et al. Systemic regulation of cancer development by neuro‐endocrine‐immune Signaling network at multiple levels. Front Cell Dev Biol. 2020;8:586757‐586768.
Dai D, Liu H. The nervous system contributes to the tumorigenesis and progression of human digestive tract cancer. J Immunol Res. 2022;2022:9595704.
Scott G, Asrat S, Allinne J, et al. IL‐4 and IL‐13, not eosinophils, drive type 2 airway inflammation, remodeling and lung function decline. Cytokine. 2023;162:156091.
Brandsma AM, Bondza S, Evers M, et al. Potent fc receptor signaling by IgA leads to superior killing of cancer cells by neutrophils compared to IgG. Front Immunol. 2019;10:704.
Evers M, Stip M, Keller K, et al. Anti‐GD2 IgA kills tumors by neutrophils without antibody‐associated pain in the preclinical treatment of high‐risk neuroblastoma. J Immunother Cancer. 2021;9(10):e003163.
Song F, Zhang Y, Chen Q, et al. Mast cells inhibit colorectal cancer development by inducing ER stress through secreting cystatin C. Oncogene. 2023;42(3):209‐223.
Fan X, Yang X, Guo N, Gao X, Zhao Y. Development of an endoplasmic reticulum stress‐related signature with potential implications in prognosis and immunotherapy in head and neck squamous cell carcinoma. Diagn Pathol. 2023;18(1):51.
Portales‐Cervantes L, Dawod B, Marshall JS. Mast cells and natural killer cells‐a potentially critical interaction. Viruses. 2019;11(6):1‐18.
Jensen‐Jarolim E, Mechtcheriakova D, Pali‐Schoell I. The targets of IgE: allergen‐associated and tumor‐associated molecular patterns. Cancer and IgE: Introducing the Concept of AllergoOncology. Humana Press; 2010:231‐254.
Munitz A, Bachelet I, Fraenkel S, et al. 2B4 (CD244) is expressed and functional on human eosinophils. J Immunol. 2004;174(1):110‐118.
Kataoka S, Konishi Y, Nishio Y, Fujikawa‐Adachi K, Tominaga A. Antitumor activity of eosinophils activated by IL‐5 and eotaxin against hepatocellular carcinoma. DNA Cell Biol. 2004;23(9):549‐560.
Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL‐5 and CCL11: a potential role for eosinophils in tumor immune surveillance. J Immunol. 2007;178(7):4222‐4229.
Lucarini V, Ziccheddu G, Macchia I, et al. IL‐33 restricts tumor growth and inhibits pulmonary metastasis in melanoma‐bearing mice through eosinophils. Oncoimmunology. 2017;6(6):e1317420.
Gatault S, Delbeke M, Driss V, et al. IL‐18 is involved in eosinophil‐mediated Tumoricidal activity against a colon carcinoma cell line by upregulating LFA‐1 and ICAM‐1. J Immunol. 2015;195(5):2483‐2492.
Legrand F, Driss V, Delbeke M, et al. Human eosinophils exert TNF‐alpha and granzyme A‐mediated tumoricidal activity toward colon carcinoma cells. J Immunol. 2010;185(12):7443‐7451.
Yamaguchi T, Kimura H, Kurabayashi M, Kozawa K, Kato M. Interferon‐γ enhances human eosinophil effector functions induced by granulocyte‐macrophage colony‐stimulating factor or interleukin‐5. Immunol Lett. 2008;118(1):88‐95.
Carretero R, Sektioglu IM, Garbi N, Salgado OC, Beckhove P, Hammerling GJ. Eosinophils orchestrate cancer rejection by normalizing tumor vessels and enhancing infiltration of CD8+ T cells. Nat Immunol. 2015;16(6):609‐617.
Arnold IC, Artola‐Boran M, Gurtner A, et al. The GM‐CSF‐IRF5 signaling axis in eosinophils promotes antitumor immunity through activation of type 1 T cell responses. J Exp Med. 2020;217(12):1‐23.
McLaughlin JP, Abrams S, Kantor J, et al. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte‐macrophage colony‐stimulating factor (GM‐CSF) induces tumor regression and long‐lasting systemic immunity. J Immunother. 1997;20(6):449‐459.
Hollande C, Boussier J, Ziai J, et al. Inhibition of the dipeptidyl peptidase DPP4 (CD26) reveals IL‐33‐dependent eosinophil‐mediated control of tumor growth. Nat Immunol. 2019;20(3):257‐264.
Ponzetta A, Carriero R, Carnevale S, et al. Neutrophils driving unconventional T cells mediate resistance against murine sarcomas and selected human Tumors. Cell. 2019;178(2):346‐360.
Singhal S, Bhojnagarwala PS, O'Brien S, et al. Origin and role of a subset of tumor‐associated neutrophils with antigen‐presenting cell features in early‐stage human lung cancer. Cancer Cell Int. 2016;30(1):120‐135.
Matlung HL, Babes L, Zhao XW, et al. Neutrophils kill antibody‐opsonized cancer cells by trogoptosis. Cell Rep. 2018;23(13):3946‐3959.
Denzel A, Maus UA, Gomez MR, et al. Basophils enhance immunological memory responses. Nat Immunol. 2008;9(7):733‐742.
Merluzzi S, Betto E, Ceccaroni AA, Magris R, Giunta M, Mion F. Mast cells, basophils and B cell connection network. Mol Immunol. 2014;63(1):94‐103.
Veglia F, Sanseviero E, Gabrilovich DI. Myeloid‐derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21(8):485‐498.
Xie F, Liu LB, Shang WQ, et al. The infiltration and functional regulation of eosinophils induced by TSLP promote the proliferation of cervical cancer cell. Cancer Lett. 2015;364(2):106‐117.
Zaynagetdinov R, Sherrill TP, Gleaves LA, et al. Interleukin‐5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. 2015;75(8):1624‐1634.
Stathopoulos GT, Sherrill TP, Karabela SP, et al. Host‐derived interleukin‐5 promotes adenocarcinoma‐induced malignant pleural effusion. Am J Respir Crit Care Med. 2010;182(10):1273‐1281.
Eiró N, González L, González LO, et al. Relationship between the inflammatory molecular profile of breast carcinomas and distant metastasis development. PLoS One. 2012;7(11):1‐9.
Panagopoulos V, Leach DA, Zinonos I, et al. Inflammatory peroxidases promote breast cancer progression in mice via regulation of the tumour microenvironment. Int J Oncol. 2017;50(4):1191‐1200.
Walsh MT, Connell K, Sheahan AM, Gleich GJ, Costello RW. Eosinophil peroxidase signals via epidermal growth factor‐2 to induce cell proliferation. Am J Respir Cell Mol Biol. 2011;45(5):946‐952.
Hennigan K, Conroy PJ, Walsh MT, et al. Eosinophil peroxidase activates cells by HER2 receptor engagement and β1‐integrin clustering with downstream MAPK cell signaling. Clin Immunol. 2016;171:1‐11.
Kratochvill F, Neale G, Haverkamp JM, et al. TNF counterbalances the emergence of M2 tumor macrophages. Cell Rep. 2015;12(11):1902‐1914.
Odemuyiwa SO, Ghahary A, Li Y, et al. Cutting edge: human eosinophils regulate T cell subset selection through indoleamine 2,3‐dioxygenase. J Immunol. 2004;173(10):5909‐5913.
Astigiano S, Morandi B, Costa R, et al. Eosinophil granulocytes account for indoleamine 2,3‐dioxygenase‐mediated immune escape in human non‐small cell lung cancer. Neoplasia. 2005;7(4):390‐396.
Marone G, Varricchi G, Loffredo S, Granata F. Mast cells and basophils in inflammatory and tumor angiogenesis and lymphangiogenesis. Eur J Pharmacol. 2015;778:146‐151.
Marone G, Gambardella AR, Mattei F, Mancini J, Schiavoni G, Varricchi G. Basophils in tumor microenvironment and surroundings. Adv Exp Med Biol. 2020;1224:21‐34.
Crivellato E, Travan L, Ribatti D. Mast cells and basophils: a potential link in promoting angiogenesis during allergic inflammation. Int Arch Allergy Immunol. 2009;151(2):89‐97.
Heneberg P. Mast cells and basophils: trojan horses of conventional lin‐stem/progenitor cell isolates. Curr Pharm des. 2011;17(34):3753‐3771.
Wculek SK, Bridgeman VL, Peakman F, Malanchi I. Early neutrophil responses to chemical carcinogenesis shape long‐term lung cancer susceptibility. iScience. 2020;23(7):101277.
Butin‐Israeli V, Bui TM, Wiesolek HL, et al. Neutrophil‐induced genomic instability impedes resolution of inflammation and wound healing. J Clin Invest. 2019;129(2):712‐726.
Antonio N, Bonnelykke‐Behrndtz ML, Ward LC, et al. The wound inflammatory response exacerbates growth of pre‐neoplastic cells and progression to cancer. EMBO J. 2015;34(17):2219‐2236.
Masson V, de la Ballina LR, Munaut C, et al. Contribution of host MMP‐2 and MMP‐9 to promote tumor vascularization and invasion of malignant keratinocytes. FASEB J. 2004;19(2):234‐236.
Zhao J, Jin J. Neutrophil extracellular traps: new players in cancer research. Front Immunol. 2022;13:937565.
Ozel I, Duerig I, Domnich M, Lang S, Pylaeva E, Jablonska J. The good, the bad, and the ugly: neutrophils, angiogenesis, and cancer. Cancers (Basel). 2022;14(3):536‐556.
Tian X, Xu W, Wang Y, et al. Identification of tumor‐infiltrating immune cells and prognostic validation of tumor‐infiltrating mast cells in adrenocortical carcinoma: results from bioinformatics and real‐world data. Onco Targets Ther. 2020;9(1):1784529.
Okcu O, Öztürk Ç, Şen B, et al. The prognostic significance of non‐lymphoid immune cells of the tumor microenvironment, including neutrophils, eosinophils, and mast cells in breast carcinomas. Ann Diagn Pathol. 2023;65:152151.
Yin X, Liu J, Wang X, et al. Identification of key transcription factors and immune infiltration patterns associated with breast cancer prognosis using WGCNA and Cox regression analysis. Front. Oncologia. 2022;11:742792.
Guo F, Kong WN, Li DW, et al. Low tumor infiltrating mast cell density reveals prognostic benefit in cervical carcinoma. Technol Cancer Res Treat. 2022;21:15330338221106530.
Huang J, Luo F, Shi M, et al. Construction and validation of a metabolic gene‐associated prognostic model for cervical carcinoma and the role on tumor microenvironment and immunity. Aging. 2021;13(23):25072‐25088.
Bazzi ZA, Sneddon S, Zhang PGY, Tai IT. Characterization of the immune cell landscape in CRC: clinical implications of tumour‐infiltrating leukocytes in early‐ and late‐stage CRC. Front Immunol. 2023;13:1‐13. Available from: https://pubmed.ncbi.nlm.nih.gov/36846019/
Mao Y, Feng Q, Zheng P, et al. Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. Int J Cancer. 2018;143(9):2271‐2280.
Yin H, Wang X, Jin N, et al. Integrated analysis of immune infiltration in esophageal carcinoma as prognostic biomarkers. Ann Transl Med. 2022;9(22):1697.
Du H, Pang S, Li Y, Zhu L, Hang J, Chen L. The prognostic value of an immune‐related gene signature and infiltrating tumor immune cells based on bioinformatics analysis in primary esophageal cancer. J Gastrointest Oncol. 2022;13(4):1556‐1570.
Guo X, Shen W, Sun M, Lv J, Liu R. Activated mast cells combined with NRF2 predict prognosis for Esophageal cancer. J Oncol. 2023;2023:4211885.
Bo X, Wang J, Wang C, et al. High infiltration of mast cells is associated with improved response to adjuvant chemotherapy in gallbladder cancer. Cancer Sci. 2020;111(3):817‐825.
Cosoroabă RM, Gaje NP, Ceauşu AR, et al. The mast cell reaction in premalignant and malignant lesions of the head and neck. Romanian J Morphol Embryol. 2022;63(2):407‐411.
Fang T, Wang Z, Yin X, et al. Evaluation of immune infiltration based on image plus helps predict the prognosis of stage III gastric cancer patients with significantly different outcomes in Northeastern China. Dis Markers. 2022;2022:2893336.
Rohr‐Udilova N, Tsuchiya K, Timelthaler G, et al. Morphometric analysis of mast cells in tumor predicts recurrence of hepatocellular carcinoma after liver transplantation. Hepatol Commun. 2021;5(11):1939‐1952.
Fan F, Gao J, Zhao Y, et al. Elevated mast cell abundance is associated with enrichment of CCR2+ cytotoxic T cells and favorable prognosis in lung adenocarcinoma. Cancer Res. 2023;83(16):2690‐2703.
Leveque E, Rouch A, Syrykh C, et al. Phenotypic and histological distribution analysis identify mast cell heterogeneity in non‐small cell lung cancer. Cancers (Basel). 2022;14(6):1394.
Guo G, Yang L, Wen Y, et al. Analysis of the tumor immune environment identifies an immune gene set‐based prognostic signature in non‐small cell lung cancer. Ann Transl Med. 2022;10(1):15.
Hou Y, Wang Q, Su L, Zhu Y, Xiao Y, Feng F. Increased tumor‐associated mast cells facilitate thyroid cancer progression by inhibiting CD8+ T cell function through galectin‐9. Braz J Med Biol Res. 2023;56:e12370.
Zadvornyi T, Lukianova N, Borikun T, et al. Mast cells as a tumor microenvironment factor associated with the aggressiveness of prostate cancer. Neoplasma. 2023;69(6):1490‐1498.
Hempel Sullivan H, Heaphy CM, Kulac I, et al. High Extratumoral mast cell counts are associated with a higher risk of adverse prostate cancer outcomes. Cancer Epidemiol Biomarkers Prev. 2020;29(3):668‐675.
Yao J, Xi W, Chen X, et al. Mast cell density in metastatic renal cell carcinoma: association with prognosis and tumour‐infiltrating lymphocytes. Scand J Immunol. 2020;93(4):e13006.
Liu Z, Zhu Y, Xu L, et al. Tumor stroma‐infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer. Onco Targets Ther. 2018;7(9):e1474317.
Jammal MP, Lopes AD, Etchebehere RM, Murta EFC, Nomelini RS. Mast cells and M2 macrophages in ovarian cancer. J Obstet Gynaecol. 2022;42(7):3094‐3100.
Cao K, Zhang G, Zhang X, et al. Stromal infiltrating mast cells identify immunoevasive subtype high‐grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response. Onco Targets Ther. 2021;10(1):1969075.
Zhao P, Zhou P, Tang T, et al. Levels of circulating mast cell progenitors and tumour‐infiltrating mast cells in patients with colorectal cancer. Oncol Rep. 2022;47(5):1‐8.
Huang R, Sun H, Yan G, et al. Co‐expression analysis of genes and tumor‐infiltrating immune cells in metastatic uterine Carcinosarcoma. Reprod Sci. 2021;28(9):2685‐2698.
Wang C, Tang X, Wang J, Xu Y. Patterns of immune infiltration in lung adenocarcinoma revealed a prognosis‐associated microRNA‐mast cells network. Hum Cell. 2020;33(1):205‐219.
Zhang E, Dai F, Mao Y, et al. Differences of the immune cell landscape between normal and tumor tissue in human prostate. Clin Transl Oncol. 2019;22(3):344‐350.
Yang Y, Qian W, Zhou J, Fan X. A mast cell‐related prognostic model for non‐small cell lung cancer. J Thorac Dis. 2023;15(4):1948‐1957.
Popov H, Donev IS, Ghenev P. Quantitative analysis of tumor‐associated tissue eosinophilia in recurring bladder cancer. Cureus. 2018;10(9):1‐6. Available from: https://pubmed.ncbi.nlm.nih.gov/30443450/
Jinno N, Yoshida M, Hayashi K, et al. Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer. Cancer Sci. 2021;112(2):668‐678.
Ohkuma R, Kubota Y, Horiike A, et al. The prognostic impact of eosinophils and the eosinophil‐to‐lymphocyte ratio on survival outcomes in stage II Resectable pancreatic cancer. Pancreas. 2021;50(2):167‐175.
Onesti CE, Josse C, Poncin A, et al. Predictive and prognostic role of peripheral blood eosinophil count in triple‐negative and hormone receptor‐negative/HER2‐positive breast cancer patients undergoing neoadjuvant treatment. Oncotarget. 2018;9(72):33719‐33733.
Onesti CE, Josse C, Boulet D, et al. Blood eosinophilic relative count is prognostic for breast cancer and associated with the presence of tumor at diagnosis and at time of relapse. Oncoimmunology. 2020;9(1):1761176. Available from: https://pubmed.ncbi.nlm.nih.gov/32923121/
Shinke G, Yamada D, Eguchi H, et al. The postoperative peak number of leukocytes after hepatectomy is a significant prognostic factor for cholangiocarcinoma. Mol Clin Oncol. 2019;10(5):531‐540. Available from: https://pubmed.ncbi.nlm.nih.gov/31007913/
Farruggia P, Puccio G, Sala A, et al. The prognostic value of biological markers in paediatric Hodgkin lymphoma. Eur J Cancer. 2016;52:33‐40.
Englund A, Molin D, Enblad G, et al. The role of tumour‐infiltrating eosinophils, mast cells and macrophages in classical and nodular lymphocyte predominant Hodgkin lymphoma in children. Eur J Haematol. 2016;97(5):430‐438.
Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor‐targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794‐5799.
Shen M, Hu P, Donskov F, Wang G, Liu Q, Du J. Tumor‐associated neutrophils as a new prognostic factor in cancer: a systematic review and meta‐analysis. PLoS One. 2014;9(6):1‐10. Available from: https://pubmed.ncbi.nlm.nih.gov/24906014/
Li J, Peng G, Zhu K, et al. PD‐1+ mast cell enhanced by PD‐1 blocking therapy associated with resistance to immunotherapy. Cancer Immunology, Immunotherapy. 2023;72(3):633‐645.
Balatoni T, Ladányi A, Fröhlich G, et al. Biomarkers associated with clinical outcome of advanced melanoma patients treated with Ipilimumab. Pathol Oncol Res. 2020;26(1):317‐325.
Martens A, Wistuba‐Hamprecht K, Foppen MG, et al. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. Clin Cancer Res. 2016;22(12):2908‐2918.
Khoja L, Atenafu EG, Templeton A, et al. The full blood count as a biomarker of outcome and toxicity in ipilimumab‐treated cutaneous metastatic melanoma. Cancer Med. 2016;5(10):2792‐2799.
Diem S, Kasenda B, Martin‐Liberal J, et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. Eur J Cancer. 2015;51(18):2785‐2791.
Ma Y, Ma X, Wang J, Wu S, Wang J, Cao B. Absolute eosinophil count may be an optimal peripheral blood marker to identify the risk of immune‐related adverse events in advanced malignant tumors treated with PD‐1/PD‐L1 inhibitors: a retrospective analysis. World J Surg Oncol. 2022;20(1):1‐11.
Tasaki Y, Hamamoto S, Sugiyama Y, et al. Elevated eosinophils proportion as predictor of immune‐related adverse events after ipilimumab and nivolumab treatment of advanced and metastatic renal cell carcinoma. Int J Urol. 2023;30(10):866‐874.
Guida M, Bartolomeo N, Quaresmini D, et al. Basal and one‐month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild‐type melanoma. J Transl Med. 2022;20(1):159.
Schalper KA, Carleton M, Zhou M, et al. Elevated serum interleukin‐8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune‐checkpoint inhibitors. Nat Med. 2020;26(5):688‐692.
Gungabeesoon J, Gort‐Freitas NA, Kiss M, et al. A neutrophil response linked to tumor control in immunotherapy. Cell. 2023;186(7):1448‐1464.